Passionately developing equitable cures for populations that have been overburdened with disease
In 1905, British physiologist Ernest Starling advanced the concept that the human body possesses a system of chemical signaling to regulate and control organ systems thus preserving the body’s living environment and balance. He called the signaling molecules “hormones” and sparked a wave of innovation leading to drugs that could mimic and go beyond the body’s natural cellular messaging systems. In 1979, the Canadian physician-scientist Adolfo DeBold reported the heart was an endocrine organ and produced and released a hormone called atrial natriuretic peptide whose action is to control blood pressure.
Today, E-Star Biotech is advancing the clinical development of a modified atrial natriuretic peptide called MANP which was engineered at the Mayo Clinic. Mayo Clinic physicians and scientists who discovered MANP through peptide engineering demonstrated MANP to be more potent and long-lasting in the body than atrial natriuretic peptide.
The therapeutic potential for MANP is great and based on its multiple beneficial biological actions may be a breakthrough therapy for hypertension, heart failure, obesity, diabetes, and renal disease.
In a recently reported First-in-Human Phase 1 clinical trial in human hypertension, MANP reduced elevated blood pressure, increased the excretion of salt, reduced the salt retaining hormone aldosterone and proved to be safe and well tolerated. A large clinical study is ongoing in a racially diverse patient population with resistant and uncontrolled hypertension.
E-Star Biotech is dedicated to innovative therapeutics for diseases with unmet needs including rare diseases. Thus E-Star Biotech is also advancing innovative drug discovery building a platform of designer natriuretic peptides which may lead to multiple novel drugs thus reducing human disease worldwide.
Other innovation projects
Developing strategies for intelligent vaccines to succeed in the future against major global diseases.